tiprankstipranks
Pharma Mar SA (ES:PHM)
BME:PHM

Pharma Mar SA (PHM) Stock Price & Analysis

2 Followers

PHM Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€25.71 - €43.17
Previous Close€32.58
Volume2.42K
Average Volume (3M)40.11K
Market Cap
€589.48M
Enterprise Value€449.69M
Total Cash (Recent Filing)€182.42M
Total Debt (Recent Filing)€42.63M
Price to Earnings (P/E)301.9
Beta0.73
Jul 25, 2024
Dividend Yield2.04%
Share Statistics
EPS (TTM)0.11
Shares Outstanding17,971,614
10 Day Avg. Volume37,764
30 Day Avg. Volume40,109
Standard Deviation0.17
R-Squared0.03
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)3.28
Price to Sales (P/S)4.26
Price to Cash Flow (P/CF)18.80
P/FCF Ratio-41.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
Price Target Upside112.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1

Financials

Annual

PHM FAQ

What was Pharma Mar SA’s price range in the past 12 months?
Pharma Mar SA lowest stock price was €25.71 and its highest was €43.16 in the past 12 months.
    What is Pharma Mar SA’s market cap?
    Currently, no data Available
    When is Pharma Mar SA’s upcoming earnings report date?
    Pharma Mar SA’s upcoming earnings report date is Jul 25, 2024 which is in 20 days.
      How were Pharma Mar SA’s earnings last quarter?
      Pharma Mar SA released its earnings results on Apr 23, 2024. The company reported €0.12 earnings per share for the quarter, beating the consensus estimate of -€0.07 by €0.19.
        Is Pharma Mar SA overvalued?
        According to Wall Street analysts Pharma Mar SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Pharma Mar SA pay dividends?
          Pharma Mar SA pays a Annually dividend of €0.53 which represents an annual dividend yield of 2.04%. See more information on Pharma Mar SA dividends here
            What is Pharma Mar SA’s EPS estimate?
            Pharma Mar SA’s EPS estimate is €0.02.
              How many shares outstanding does Pharma Mar SA have?
              Pharma Mar SA has 18,554,108 shares outstanding.
                What happened to Pharma Mar SA’s price movement after its last earnings report?
                Pharma Mar SA reported an EPS of €0.12 in its last earnings report, beating expectations of -€0.07. Following the earnings report the stock price went up 4.075%.
                  Which hedge fund is a major shareholder of Pharma Mar SA?
                  Currently, no hedge funds are holding shares in ES:PHM
                  ---

                  Pharma Mar SA Stock Smart Score

                  10
                  Unlock Smart Score
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Fundamentals

                  Return on Equity
                  1.03%
                  Trailing 12-Months
                  Asset Growth
                  -11.19%
                  Trailing 12-Months

                  Company Description

                  Pharma Mar SA

                  Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and market insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology, Diagnostics, Consumer chemicals, and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
                  ---

                  PHM Earnings Call

                  Q4 2024
                  0:00 / 0:00
                  ---

                  PHM Stock 12 Month Forecast

                  Average Price Target

                  €70.00
                  ▲(112.45% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"€26","71":"€71","37.25":"€37.3","48.5":"€48.5","59.75":"€59.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70.000000229005,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">€70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70.0025403,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">€70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70.000000229005,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">€70.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,37.25,48.5,59.75,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2023","6":"Jan<br/>2024","9":"Apr<br/>2024","12":"Jun<br/>2024","25":"Jun<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.347,39.858769248385,42.37053849677,44.882307745155,47.39407699354,49.905846241925005,52.41761549031,54.929384738695,57.44115398708,59.952923235465,62.46469248385,64.976461732235,67.48823098062,{"y":70.000000229005,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.347,39.85896463846154,42.37092927692308,44.88289391538462,47.394858553846156,49.9068231923077,52.41878783076923,54.930752469230775,57.44271710769232,59.95468174615385,62.46664638461539,64.97861102307692,67.49057566153847,{"y":70.0025403,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.347,39.858769248385,42.37053849677,44.882307745155,47.39407699354,49.905846241925005,52.41761549031,54.929384738695,57.44115398708,59.952923235465,62.46469248385,64.976461732235,67.48823098062,{"y":70.000000229005,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":29.937,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":34.615,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":34.929,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":31.548,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":31.352,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":37.878,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":41.495,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":36.895,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":30.133,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.381,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.244,"date":1712880000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.605,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.347,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Pharma Mar SA
                  Crispr Therapeutics AG
                  Moderna
                  RegenXBio
                  Fate Therapeutics

                  Best Analysts Covering PHM

                  1 Year
                  Ami FadiaNeedham
                  1 Year Success Rate
                  1/4 ratings generated profit
                  25%
                  1 Year Average Return
                  -23.90%
                  reiterated a buy rating 3 months ago
                  Copying Ami Fadia's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -23.90% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis